Ulcerative Colitis news | Breaking ulcerative colitis news

Isis Pharmaceuticals Reports Clinical Development Goals

...* Partner and prepare to initiate a Phase 3 program (2H06) Partner Pipeline Milestones projected for our partnered drugs: OncoGenex OGX-011 (Targeting Clusterin for the treatment of breast, prostate and lung cancers) * Advance four Phase 2 clinical trials * Report Phase 1 data in NSCLC (2Q06) Eli Lilly LY2181308 (Targeting Survivin for the treatment of cancer) * Initiate Phase 2 clinical trials (4Q06) LY2275796 (Targeting eIF-4E for the treatment of cancer) * Progress Phase 1 clinical trials in patients with cancer Antisense Therapeutics Limited ATL-1102 (Targeting VLA4 for the treatment of Multiple Sclerosis) * Progress Phase 2 studies in patients with Multiple Sclerosis iCo Therapeutics iCo 007 (Targeting c-raf kinase for the treatment of eye diseases) * Initiate Phase 1 clinical trials (4Q06/1Q07) Isis will conduct a live webcast conference call to discuss this press release on Friday, February 10 at 8:30am Eastern time.

To participate over the Internet go to http://www.videonewswire.com/event.asp?

id=32301 or http://www.isispharm.com/.

A replay of the webcast will be available at these addresses for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.

The Company has successfully commercialized the world's first antisense drug and has 12 antisense drugs in development to treat metabolic, cardiovascular, ocular and inflammatory...

Ulcerative Colitis

News

Advertisers:

Isis Pharmaceuticals Reports Clinical Development Goals